Sabat, Mark <br/><br/>
The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).  [electronic resource] 

 -  Bioorganic & medicinal chemistry letters  Aug 2006 
 - 4257-61 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0960-894X 
<br/><br/><label>Standard No.: </label>10.1016/j.bmcl.2006.05.072  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Drug Design<br/>Drug Industry--methods<br/>Enzyme Inhibitors--chemistry<br/>Humans<br/>Inhibitory Concentration 50<br/>Lymphocyte Specific Protein Tyrosine Kinase p56(lck)--antagonists & inhibitors<br/>Lymphocytes--metabolism<br/>Models, Chemical<br/>Models, Molecular<br/>Pyridazines--chemistry<br/>Pyrimidines--chemistry<br/>Ribonucleosides--chemistry<br/>Structure-Activity Relationship